Patients must be able to undergo MRI of the brain with gadolinium; patients must be maintained on a stable or decreasing dose of corticosteroid regimen (no increase for 5 days) prior to this baseline MRI
Stable dose of corticosteroids for at least 7 days
If patients are on corticosteroids, they must have been on a stable or decreasing dose >= 5 days prior to obtaining their baseline gadolinium (Gd)-magnetic resonance imaging (MRI) of brain; this MRI is to be obtained within 28 days of registration; NOTE: If patient needs escalation of steroids prior to therapy, or are on unstable doses of steroids they are not eligible
For subjects on corticosteroids for endocrine deficiencies or tumor-associated symptoms, must be on a stable (or decreasing) dose for at least 7 days before first dose of study treatment.
Participants must have bi-dimensionally measurable disease with a minimum measurement of 1 cm per dimension on MRI performed within 14 days prior to registration; if receiving corticosteroids, participants must be on a stable or decreasing dose of corticosteroids for at least 5 days prior to baseline MRI
Patients receiving unstable or increasing doses of corticosteroids; if patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms other than CNS related, dose must have been stabilized (or decreasing) for at least 5 days before first dose of INC280
Patients enrolling in the medical arm (Arms C and D) must be on a stable or decreasing dose of corticosteroids (or none) for at least 5 days prior to the baseline MRI;
Phase I patients must be maintained on a stable corticosteroid regimen (no increase for 5 days) prior to the baseline MRI
Stable disease (SD) for >=30 days, without steroid use (or stable steroid dose established for >=14 days before the first dose of TAK-931).
To document the degree of tumor at study baseline, the following scan(s) must be obtained: • A brain MRI with and without contrast (ie, gadolinium) and a spine MRI with contrast within 21 days prior to first dose of study treatment. For subjects on steroids, baseline MRI scans must be performed while on stable or decreasing dose of steroids for at least 5 days.
Participants receiving corticosteroids who have not been on a stable dose for at least 7 days prior to study drug administration.
Patients must be on a stable or decreasing dose of corticosteroids within 5 days prior to CT scan or MRI (which is done to determine eligibility); patients must be on no more than 8 mg a day but an attempt should be made to keep the dose at 4 mg or less; please contact the PI if doses of > 4 mg are needed
Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. Subjects previously treated for these conditions that have had stable central nervous system (CNS) disease (verified with consecutive imaging studies) for >1 month , are asymptomatic and off corticosteroids, or are on stable dose of corticosteroids for at least 1 month prior to study Day 1 are permitted. Stability of brain metastases must be confirmed with imaging. Subject treated with gamma knife therapy can be enrolled 2 weeks post-procedure as long as there are no post-procedure complications/they are stable. This criterion does not apply to subjects with GBM cohort. In Part 1, subjects with GBM may enroll provided that they are on a stable to decreasing dose of corticosteroids for at least 14 days prior to the first dose of GSK3326595. In Part 2, subjects with GBM may enroll irrespective of steroid dose.
If receiving corticosteroids, patients must be on a stable or decreasing dose of corticosteroids for ? 5 days prior to baseline MRI.
CAPMATINIB EXCLUSION CRITERIA: Patients on unstable or increasing doses of corticosteroids; if patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms other than CNS related, dose must have been stabilized or decreasing for at least 5 days before first dose of capmatinib
For subjects on corticosteroids, they must be on a stable dose for 7 days prior to anticipated start of study drug
If receiving eltrombopag or romiplostim, the dose must have been stable for ? 21 days prior to the first dose of PRTX-100
If on steroid-sparing adjunctive immunosuppression with cyclosporine, azathioprine, mycophenolate, or 6-mercaptopurine, the dose must have been stable for ? 30 days prior to the first dose of PRTX-100 and must be expected to remain stable through study Day 29, unless dose reduction is required due to toxicities. Treatment with other cytotoxic agents (e.g. cyclophosphamide, vincristine) are not allowed within three months prior to the first dose of PRTX- 100.
Patients must be on stable dose of steroids for at least 5 days prior to baseline imaging
Have brain metastases that are neurologically unstable or require an increasing dose of corticosteroids. Patients must be on a stable or decreasing dose of corticosteroids for 7 days prior to first dose of AP32788.
If receiving concomitant corticosteroids, must be on a stable or decreasing dose for at least 7 days prior to the baseline Gd-MRI.
Corticosteroids: Participants receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to study drug administration (except when indicated for Central Nervous System [CNS] metastases, then participants must not have received corticosteroids for at least 28 days)
Stable dose of corticosteroids for CNS metastasis for > 7 days
Stable or decreasing dose of steroids for at least 5 days at the time of baseline brain MRI.
Fixed or decreasing dose of corticosteroids (or no corticosteroids) >= 7 days prior to registration
Patients must be maintained on a stable corticosteroid regimen (no increase for 5 days) prior to the baseline MRI
Patients must be maintained on a stable corticosteroid regimen (no increase for 5 days) prior to the baseline MRI
Baseline MRI within 17 days of Day 1 & on steroid dosage that has been stable or decreasing for at least 5 days
Patients must be able to undergo MRI of the brain with gadolinium; patients must be maintained on a stable or decreasing dose of corticosteroid regimen (no increase for 5 days) prior to this baseline MRI
If corticosteroids are required for controlling cerebral edema, patients must be on a stable dose of at least 1 week prior to enrollment
Solid tumor patients must be off corticosteroids prior to registration; if GBM patient is receiving corticosteroids, patient must be on a stable or decreasing dose of corticosteroids for at least 5 days prior to baseline magnetic resonance imaging (MRI) or computed tomography (CT); if steroids are added or the steroids dose is increased between the date of the screening MRI or CT and the start of treatment, a new baseline MRI or CT is required
Stable systemic disease
Co-medication that may interfere with study results, e.g., immuno-suppressive agents other than corticosteroids. (Steroid therapy for control of cerebral edema is allowed at the discretion of the Investigator. Subjects should be on a stable dose of steroids for at least 1 week prior to first dose of MRZ.)
Other ongoing anti-myeloma therapy. Patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids for symptom management and comorbid conditions. Doses of corticosteroid should be stable for at least 7 days prior to patient registration.
Neurologically stable defined as receiving no, stable, or tapering doses of corticosteroids for >= 5 days prior to drug dosing; treatment with corticosteroids during the study is allowed, and can be adjusted by the investigator during the study; changes in steroid dose are incorporated into the Revised Assessment in Neuro-Oncology (RANO) imaging criteria
If receiving corticosteroids, patients must be on a stable or decreasing dose of corticosteroids for ? 5 days prior to baseline MRI.
Patients must be on a stable or decreasing dose of corticosteroids for a minimum of 5 days before the baseline MRI/CT; if the corticosteroid dose is increased between the date of imaging and the initiation of study treatment, a new baseline MRI/CT is required; definition of stable steroids includes patients on no steroids
Fixed or decreasing dose of corticosteroids (or no corticosteroids) >= 7 days prior to registration
Presence of brain metastases (except for subjects in the WHO Grade 1 or 2 or 3 or 4 glioma histology cohorts) that are symptomatic or untreated or not stable for >=3 months (must be documented by imaging) or requiring corticosteroids. Subjects on a stable dose of corticosteroids >14 days and have not required treatment with enzyme-inducing anticonvulsants for >30 days prior to enrollment can be enrolled with approval of the Medical Monitor
Presence of symptomatic or untreated leptomeningeal or spinal cord compression. Subjects who have been previously treated for these conditions and have stable CNS disease (documented by consecutive imaging studies) for >60 days, are asymptomatic and currently not taking corticosteroids, or have been on a stable dose of corticosteroids for at least 30 days prior to enrollment, are permitted
Patients must have been on a stable dose of corticosteroids >= 5 days prior to obtaining their baseline gadolinium (Gd)-MRI of brain
Patients must be on a stable or decreased dose of steroids for at least 5 days prior to baseline imaging
Patients must be on a stable or decreasing dexamethasone dosage for at least 1 week prior to baseline MRI
Steroids: patients who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to baseline MRI
The baseline on-study MRI should be performed within 14 days (+ 3 working days) prior to registration and on a steroid dosage that has been stable or decreasing for at least 5 days. If the steroid dose is increased between the date of imaging and the initiation of therapy (or at that time), a new baseline MRI is required. The same type of scan, i.e., MRI, must be used throughout the period of protocol treatment for tumor measurement.
Baseline MRI must be performed after subject signs informed consent form (ICF), within 17 days of Day 1, & on steroid dosage that has been stable or decreasing for at least 5 days
Patients can be on steroids as long as the dose has been stable for >= 7 days
Patients receiving unstable or increasing doses of corticosteroids. If patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms, dose must have been stabilized (or decreasing) for at least 5 days before first dose of study treatment.
Fixed or decreasing dose of corticosteroids (or no corticosteroids) >= 7 days prior to registration
Patients must be on a steroid dose that has been stable or decreasing for at least 5 days; if the steroid dose is increased between the date of imaging and registration, a new baseline MRI is required
If the steroid dose is increased between the date of the MRI and registration on the trial, a new baseline MRI is required; this MRI must be performed after >= 5 days on a stable dose of steroids
Unstable or increasing doses of corticosteroids; if patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms (non-CNS), dose must have been stabilized (or decreasing) for at least 5 days before first dose of study treatment\r\n* Topical and inhaled steroids are allowed
Must have been taking a stable dose of corticosteroids for symptom management for at least 1 week before baseline MRI
Stable dose of corticosteroids for 2 weeks prior to enrollment
For patients on higher than physiological level of corticosteroids, they must have been on a stable dose for 1 week prior to initiating study drug, and the dose should not be escalated over entry dose level, if clinically possible
Subjects with a history of CNS metastases must have completed definitive treatment prior to first dose of study treatment, off or on a stable dose of corticosteroids
Corticosteroid dose must be stable or decreasing for at least 5 days prior to the baseline MRI scan
Patients receiving corticosteroids must have been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
Corticosteroids: Patients receiving corticosteroids must have been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
Patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to enrollment
Patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the 7 days prior to enrollment are not eligible
Patients who are on dexamethasone must be on a stable or decreasing dose for at least one week prior to registration
Subjects receiving corticosteroids must be on a stable or decreasing dose of corticosteroid for the prior 7 days
Steroid regimen stable or decreasing for at least 7 days prior to inoculation
Patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the 7 days prior to enrollment are not eligible.
Patients receiving systemic corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of systemic corticosteroid; Note: patients who are using topical or inhaled corticosteroids are eligible
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible
Corticosteroids: patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration
Stable or decreasing steroid dose within 2 weeks of first dose of study drug if patient is taking steroids. No steroid use is also acceptable.
For patients with HGG and receiving glucocorticoid therapy, must be on stable or decreasing equivalent daily dose of glucocorticoids for 2 weeks (14 days) prior to dose assignment
Corticosteroids: patients who are receiving dexamethasone or other corticosteroids must be on a stable or decreasing dose for at least 1 week prior to enrollment; it is recommended that patients be off all steroid therapy or receive the least dose that will control their neurologic symptoms
If on corticosteroids for mass effect and/or edema related to the tumor, patient must be on a stable or decreasing dose for at least 2 weeks prior to study entry
Corticosteroids: Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration.
STRATUM A: Participants who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to study enrollment with no plans for escalation
STRATUM B: Participants who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to study enrollment with no plans for escalation
STRATUM C: Participants who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to study enrollment with no plans for escalation
Corticosteroid dose must be stable or decreasing for at least 3 days prior to the baseline MRI scan.
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
Corticosteroids: patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration
Corticosteroid dose must be stable or decreasing for at least 3 days prior to the baseline CT or MRI scan
Patients requiring steroids must be at a stable or decreasing dose for at least 1 week prior to enrollment
Increasing corticosteroid dose in 7 days prior to administration of first dose of study drug. Symptomatic patients who have stable or decreasing corticosteroid use in the past 7 days may be included
Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration
Stable or decreasing steroid dose (=< 4 mg/day) at time of post-external beam radiation therapy (XRT) adjuvant TMZ initiation; if patients are decreasing steroid use, once they are at 2 mg/day, they may be supplemented with hydrocortisone, at the discretion of the treating oncologist
Currently on the following concomitant medications or substances that have the potential to affect the activity or pharmacokinetics of the study drug(s); the use of the following medications should be discontinued prior to initiation of protocol therapy and should be avoided during protocol therapy if reasonable alternatives exist\r\n* Sorafenib\r\n* Irinotecan\r\n* Corticosteroids: Patients requiring corticosteroids that have not been on a stable or decreasing dose of corticosteroid for 7 days prior to enrollment are not eligible
Stable and/or decreasing dose of corticosteroids for greater than or equal to 7 days.
Subjects who are receiving corticosteroids must be on a stable or decreasing dose for at least 4 weeks before first dose of study treatment.
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible.
Steroids: patients who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior enrollment in the study
Patients must be maintained on a stable or decreasing corticosteroid regimen from the time of their baseline scan until registration
Patients with corticosteroid requirements to control cerebral edema must be maintained at a stable or decreasing dose for a minimum of two weeks without progression of clinical symptoms
If patient is on corticosteroids, the dose must be stable or decreasing for at least 5 days prior to enrollment
Patients who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to registration
If patient is receiving steroids, must be on stable or decreasing steroid dose within 5 days prior to treatment initiation with SGT-53.
Must be maintained on a stable or decreasing corticosteroid regimen (no increase for 7 days) prior to the start of treatment
Patients requiring escalation of the corticosteroid dose will be excluded, but patients receiving a stable or decreasing dose for at least one week will be eligible
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
Patients who were receiving corticosteroids have to receive a stable or decreasing dose for at least 14 days before study entry
Documentation of steroid doses 10-14 days prior to study registration and stable or decreasing steroid dose over the week prior to registration
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the prior 7 days are not eligible
Stable or decreasing dose of corticosteroids within 5 days prior to study 5. enrollment.
Concurrent use of iron-chelating agents, (except for subjects on a stable or decreasing dose for at least 8 weeks (56 days) prior to randomization), corticosteroid (except for subjects on a stable or decreasing dose for ? 1 week prior to randomization for medical conditions other than MDS)
Stable or decreasing dose of corticosteroids prior to treatment with a goal of 4 mg or less of dexamethasone
For those patients in which steroids are clinically indicated, there must be a stable or decreasing dose of steroid medication for >= one week prior to the start of infusion
Corticosteroids: If used to modify immune adverse events related to prior therapy, ?14 days must have elapsed since last dose of corticosteroid. Participants receiving corticosteroids, who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment, are not eligible
Patients must be on a stable or decreasing dose of steroids for at least two weeks prior to randomization
Subjects who are receiving concomitant corticosteroids must be on a stable or decreasing dose for at least 4 weeks prior to first dose of study treatment and off all anticonvulsants for at least 4 weeks prior to study entry.
Patients must have no residual neurologic symptoms while taking no steroids, a stable or decreasing dose of steroids, or a stable dose of anti-seizure medication for the 2 weeks prior to enrollment.
Patients who are not on a stable or decreasing steroid dose for the previous week prior to the first dose of study enrollment
If receiving corticosteroids, patients must have been on a stable or decreasing dose of corticosteroids and no more than 8 mg dexamethasone (or equivalent) for at least 5 days prior to date of enrollment.
Patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the prior 7 days
At least 4 weeks post-craniotomy (7 days for stereotactic biopsy), within 14 days prior to the start of SL-701, and on a corticosteroid dosage that has been stable or decreasing for at least 5 days.
Stable or decreasing dose of corticosteroids for at least 7 days prior to randomization.
Neurological symptoms related to brain metastasis that are not controlled with a stable or decreasing dose of oral steroids for at least 7 days prior to starting GSK2118436
if receiving corticosteroids, dose is stable or decreasing for past 7 days
Steroids: Dose should be stable or decreasing for at least one week prior to starting therapy; corticosteroid therapy is permissible only for the treatment of increased intracranial pressure in patients with malignancies in the CNS or for spinal cord compression; corticosteroid should be used at the lowest dose to control symptoms and discontinued if possible
Patients must have adequate seizure control and be on a stable, or decreasing, dose of anti-epileptics
Patient must be maintained on a stable or decreasing dose of corticosteroid for at least 5 days before the baseline scan.
Concurrent use of corticosteroids unless the subject is on a stable or decreasing dose for ? 1 week prior to enrollment for medical conditions other than MDS (MYELODYSPLASTIC SYNDROMES)
On a stable or decreasing dose of dexamethasone for the previous 7 days
Patients receiving corticosteroids are eligible provided the dose is stable or decreasing for at least 7 days
Stable or decreasing dose of corticosteroids over 14 days prior to first MRZ dose
Neurologic status\r\n* Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment\r\n* Patients with seizure disorders may be enrolled if seizures are well controlled on an anti-epileptic drug that is not a strong inducer or inhibitor of CYP3A4/5 are eligible
Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration
Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration
Patients with neurological deficits should have deficits that are completely stable for a minimum of 1 week (7 days) prior to enrollment
INCLUSION CRITERIA FOR STRATUM C: Patients with neurological deficits should have deficits that are completely stable for a minimum of 1 week (7 days) prior to enrollment
Patients with neurological deficits that are stable for a minimum of one week prior to registration
Any neurologic deficits must be stable for >= 1 week
Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration
Patients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to registration
Cerebrovascular accident (CVA) with persistent neurologic deficits occurring within 6 months prior to enrollment; persisting neurologic deficits from a CVA occurring over 6 months prior to enrollment are not necessarily grounds for exclusion
Stable neurologic deficits on a stable dose of corticosteroids (if applicable) for at least 1 week before study enrollment
At the time of study enrollment patients must have a life expectancy of greater than or equal to 2 months; neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of 1 week prior to study enrollment
Neurologic deficits must have been relatively stable for a minimum of 1 week prior to study enrollment
Patients with neurological deficits should be stable for a minimum of 1 week prior to enrollment
Patients with neurological deficits should have deficits that are stable or improving for a minimum of 1 week prior to registration
Neurologic status\r\n* Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment\r\n* Patients with seizure disorders may be enrolled if seizures are well controlled
Any active neurologic and/or psychiatric disease, history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities
Patient with multiple, serious major neurologic deficits including encephalopathy.
Any neurologic deficits must be stable for >= 1 week
Neurologic deficits that are rapidly progressing: all neurologic signs and symptoms must have been stable for a week prior to first dose
Neurological deficits must be stable on a fixed or decreasing dose of dexamethasone for >= 7 days before study enrollment
Any neurologic deficits must be stable for >= 1 week
Neurologic deficits that are rapidly progressing; all neurologic signs and symptoms must have been stable for a week prior to first dose
DONOR: Severe neurologic deficits
Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration; this is to be documented at baseline
Neurologic deficits: Patients with central nervous system (CNS) tumors must have stable neurological deficits for a minimum of 1 week prior to study entry
For patients with CNS tumors (primary or metastatic), any baseline neurologic deficits (including seizure) must be stable for at least one week prior to study enrollment
No orthopedic restrictions or neurologic deficits that would limit ability to complete the Power Protocol (based on the opinion of the investigator)